View Future GrowthGenomtec 과거 순이익 실적과거 기준 점검 0/6Genomtec은 연평균 0.1%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 55.6%의 비율로 감소했습니다.핵심 정보0.14%순이익 성장률14.52%주당순이익(EPS) 성장률Biotechs 산업 성장률56.32%매출 성장률-55.58%자기자본이익률-131.28%순이익률-30,710.00%다음 순이익 업데이트30 Sep 2026최근 과거 실적 업데이트Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.공시 • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공시 • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).모든 업데이트 보기Recent updatesNew Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m).New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m).Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.공시 • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025New Risk • May 18New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m).공시 • May 12Genomtec S.A., Annual General Meeting, Jun 05, 2025Genomtec S.A., Annual General Meeting, Jun 05, 2025.Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m).공시 • May 31Genomtec S.A., Annual General Meeting, Jun 25, 2024Genomtec S.A., Annual General Meeting, Jun 25, 2024.New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m).공시 • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m).New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m).Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).공시 • Jun 02Genomtec S.A., Annual General Meeting, Jun 27, 2023Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.분석 기사 • May 09Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...공시 • Feb 03+ 1 more updateGenomtec S.A. to Report Q2, 2023 Results on Aug 11, 2023Genomtec S.A. announced that they will report Q2, 2023 results on Aug 11, 2023공시 • Mar 19+ 3 more updatesGenomtec S.A. to Report Fiscal Year 2020 Results on May 27, 2021Genomtec S.A. announced that they will report fiscal year 2020 results on May 27, 2021매출 및 비용 세부 내역Genomtec가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:GMT 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-96031 Dec 250-106030 Sep 250-116030 Jun 250-127031 Mar 250-129031 Dec 240-119030 Sep 240-1211030 Jun 240-1111031 Mar 240-1010031 Dec 230-99030 Sep 230-1310030 Jun 230-129031 Mar 230-139031 Dec 220-129030 Sep 220-86030 Jun 220-76031 Mar 220-65031 Dec 210-75030 Sep 210-1412030 Jun 210-1412031 Mar 210-1212031 Dec 200-11110양질의 수익: GMT 은(는) 현재 수익성이 없습니다.이익 마진 증가: GMT는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: GMT는 수익성이 없지만 지난 5년 동안 연평균 0.1%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 GMT의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: GMT은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(4.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: GMT는 현재 수익성이 없으므로 자본 수익률이 음수(-131.28%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/25 01:17종가2026/06/25 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genomtec S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.
공시 • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025
Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공시 • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024
Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m).
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m).
Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.
공시 • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025
New Risk • May 18New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m).
공시 • May 12Genomtec S.A., Annual General Meeting, Jun 05, 2025Genomtec S.A., Annual General Meeting, Jun 05, 2025.
Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m).
공시 • May 31Genomtec S.A., Annual General Meeting, Jun 25, 2024Genomtec S.A., Annual General Meeting, Jun 25, 2024.
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m).
공시 • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024
New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m).
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m).
Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).
공시 • Jun 02Genomtec S.A., Annual General Meeting, Jun 27, 2023Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.
분석 기사 • May 09Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
공시 • Feb 03+ 1 more updateGenomtec S.A. to Report Q2, 2023 Results on Aug 11, 2023Genomtec S.A. announced that they will report Q2, 2023 results on Aug 11, 2023
공시 • Mar 19+ 3 more updatesGenomtec S.A. to Report Fiscal Year 2020 Results on May 27, 2021Genomtec S.A. announced that they will report fiscal year 2020 results on May 27, 2021